OBJECTIVE: A retrospective review of all diagnosed cases of esthesioneuroblastoma registered in Denmark between 1978 and 2000 was carried out in order to obtain epidemiological data and optimize national treatment guidelines. MATERIAL AND METHODS: Forty cases were verified histologically and included in the analysis Epidemiological and histopathological data were evaluated in relation to the clinical outcome. RESULTS: The 40 cases represent an incidence rate of 0.4 cases/million inhabitants per year. Eight (20%) patients were classified as Kadish stage A, 13 (32.5%) as stage B and 19 (47.5%) as stage C. The histopathological findings were classified according to the grading system of Hyams The median follow-up time was 2.3 years (range 0.3-11.1 years). The 5-year crude survival rate was 61%, with a median survival of 3.1 years (range 0.3-19.2 years). The 5-year disease-free survival rate was 50%, with a median survival of 1.7 years (range 0-19.2 years). Only 3 (7%) patients had positive cervical lymph nodes at presentation. A nationwide consensus regarding treatment was seen in patients classified as Kadish stages A and B. The longest duration before the first recurrence of esthesioneuroblastoma was 5(1/2) years. CONCLUSIONS: The following therapeutic guidelines are suggested: Kadish stage A patients, surgical tumour resection and radiotherapy; Kadish stage B, surgical tumour resection and radiotherapy; Kadish stage C, surgical tumour resection via a craniofacial resection and radiotherapy combined with chemotherapy. Long-term follow-up of esthesioneuroblastoma patients is mandatory.
OBJECTIVE: A retrospective review of all diagnosed cases of esthesioneuroblastoma registered in Denmark between 1978 and 2000 was carried out in order to obtain epidemiological data and optimize national treatment guidelines. MATERIAL AND METHODS: Forty cases were verified histologically and included in the analysis Epidemiological and histopathological data were evaluated in relation to the clinical outcome. RESULTS: The 40 cases represent an incidence rate of 0.4 cases/million inhabitants per year. Eight (20%) patients were classified as Kadish stage A, 13 (32.5%) as stage B and 19 (47.5%) as stage C. The histopathological findings were classified according to the grading system of Hyams The median follow-up time was 2.3 years (range 0.3-11.1 years). The 5-year crude survival rate was 61%, with a median survival of 3.1 years (range 0.3-19.2 years). The 5-year disease-free survival rate was 50%, with a median survival of 1.7 years (range 0-19.2 years). Only 3 (7%) patients had positive cervical lymph nodes at presentation. A nationwide consensus regarding treatment was seen in patients classified as Kadish stages A and B. The longest duration before the first recurrence of esthesioneuroblastoma was 5(1/2) years. CONCLUSIONS: The following therapeutic guidelines are suggested: Kadish stage A patients, surgical tumour resection and radiotherapy; Kadish stage B, surgical tumour resection and radiotherapy; Kadish stage C, surgical tumour resection via a craniofacial resection and radiotherapy combined with chemotherapy. Long-term follow-up of esthesioneuroblastomapatients is mandatory.
Authors: Guillaume De Bonnecaze; B Lepage; J Rimmer; A Al Hawat; B Vairel; E Serrano; B Chaput; S Vergez Journal: Eur Arch Otorhinolaryngol Date: 2014-10-17 Impact factor: 2.503
Authors: Jamie J Van Gompel; Michael J Link; Jason P Sheehan; Zhiyuan Xu; David Mathieu; Hideyuki Kano; L Dade Lunsford Journal: J Neurol Surg B Skull Base Date: 2014-06-04
Authors: Victoria E Banuchi; Laura Dooley; Nancy Y Lee; David G Pfister; Sean McBride; Nadeem Riaz; Mark H Bilsky; Ian Ganly; Jatin P Shah; Dennis H Kraus; Luc G T Morris Journal: Laryngoscope Date: 2016-02-10 Impact factor: 3.325
Authors: Wen Jiang; Abdallah S R Mohamed; Clifton David Fuller; Betty Y S Kim; Chad Tang; G Brandon Gunn; Ehab Y Hanna; Steven J Frank; Shirley Y Su; Eduardo Diaz; Michael E Kupferman; Beth M Beadle; William H Morrison; Heath Skinner; Stephen Y Lai; Adel K El-Naggar; Franco DeMonte; David I Rosenthal; Adam S Garden; Jack Phan Journal: Pract Radiat Oncol Date: 2015-11-10
Authors: Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy Journal: J Neurol Surg B Skull Base Date: 2017-11-01
Authors: F Tramacere; S Bambace; M C De Luca; R Castagna; M C Francavilla; A Leone; S Monastero; F Fucilli; G Pili; M Portaluri Journal: Acta Otorhinolaryngol Ital Date: 2008-08 Impact factor: 2.124